Recombinant
RabMAb

Recombinant Anti-Insulin Receptor (phospho Y1185) antibody [EP351(2)Y] (ab62321)

Overview

  • Product name

    Anti-Insulin Receptor (phospho Y1185) antibody [EP351(2)Y]
    See all Insulin Receptor primary antibodies
  • Description

    Rabbit monoclonal [EP351(2)Y] to Insulin Receptor (phospho Y1185)
  • Host species

    Rabbit
  • Specificity

    ab62321 detects Insulin Receptor when phosphorylated at Tyrosine 1185.
  • Tested applications

    Suitable for: WB, IP, ICCmore details
    Unsuitable for: Flow Cyt or IHC-P
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic phosphopeptide corresponding to residues surrounding Tyrosine 1185 of the human Insulin Receptor.

  • Positive control

    • HepG2 cell lysate.
  • General notes

    A trial size is available to purchase for this antibody.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab62321 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/2000. Detects a band of approximately 95 kDa (predicted molecular weight: 156 kDa).
IP 1/20.
ICC 1/100 - 1/250.
  • Application notes
    Is unsuitable for Flow Cyt or IHC-P.
  • Target

    • Function

      Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.
    • Tissue specificity

      Isoform Long and isoform Short are predominantly expressed in tissue targets of insulin metabolic effects: liver, adipose tissue and skeletal muscle but are also expressed in the peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta vascular endothelium, fibroblasts, monocytes, granulocytes, erythrocytes and skin. Isoform Short is preferentially expressed in fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Overexpressed in several tumors, including breast, colon, lung, ovary, and thyroid carcinomas.
    • Involvement in disease

      Rabson-Mendenhall syndrome
      Leprechaunism
      Diabetes mellitus, non-insulin-dependent
      Familial hyperinsulinemic hypoglycemia 5
      Insulin-resistant diabetes mellitus with acanthosis nigricans type A
    • Sequence similarities

      Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.
      Contains 3 fibronectin type-III domains.
      Contains 1 protein kinase domain.
    • Domain

      The tetrameric insulin receptor binds insulin via non-identical regions from two alpha chains, primarily via the C-terminal region of the first INSR alpha chain. Residues from the leucine-rich N-terminus of the other INSR alpha chain also contribute to this insulin binding site. A secondary insulin-binding site is formed by residues at the junction of fibronectin type-III domain 1 and 2.
    • Post-translational
      modifications

      After being transported from the endoplasmic reticulum to the Golgi apparatus, the single glycosylated precursor is further glycosylated and then cleaved, followed by its transport to the plasma membrane.
      Autophosphorylated on tyrosine residues in response to insulin. Phosphorylation of Tyr-999 is required for binding to IRS1, SHC1 and STAT5B. Dephosphorylated by PTPRE at Tyr-999, Tyr-1185, Tyr-1189 and Tyr-1190. Dephosphorylated by PTPRF and PTPN1. Dephosphorylated by PTPN2; down-regulates insulin-induced signaling.
    • Cellular localization

      Cell membrane.
    • Information by UniProt
    • Database links

    • Alternative names

      • CD220 antibody
      • HHF5 antibody
      • human insulin receptor antibody
      • Insr antibody
      • INSR_HUMAN antibody
      • Insulin receptor subunit beta antibody
      • IR 1 antibody
      • IR antibody
      • IR-1 antibody
      • IR1 antibody
      see all

    Images

    • All lanes : Anti-Insulin Receptor (phospho Y1185) antibody [EP351(2)Y] (ab62321) at 1/500 dilution

      Lane 1 : HepG2 cell lysate; untreated
      Lane 2 : HepG2 cell lysate; Insulin treated

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : goat anti-rabbit HRP conjugated, at 1/2000 dilution

      Predicted band size: 156 kDa
      Observed band size: 95 kDa
      why is the actual band size different from the predicted?



      Beta Tubulin has been included as a loading control.

    References

    This product has been referenced in:

    • Ding D  et al. Genetic variation in PTPN1 contributes to metabolic adaptation to high-altitude hypoxia in Tibetan migratory locusts. Nat Commun 9:4991 (2018). Read more (PubMed: 30478313) »
    • Kong Q  et al. SP600125 induces Src and type I IGF receptor phosphorylation independent of JNK. Int J Mol Sci 15:16246-56 (2014). Read more (PubMed: 25226534) »
    See all 2 Publications for this product

    Customer reviews and Q&As

    1-3 of 3 Abreviews or Q&A

    Application
    Western blot
    Sample
    Drosophila melanogaster Cell lysate - whole cell (S2 cells)
    Gel Running Conditions
    Reduced Denaturing (10%)
    Loading amount
    50 µg
    Treatment
    10µg/ml of Bovine Insulin for 15 min
    Specification
    S2 cells
    Blocking step
    Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

    Abcam user community

    Verified customer

    Submitted Jul 11 2018

    Question
    Answer



    I don't believe we have specifically tested for cross reactivity of ab62321 with the IGF1 receptor. However, based on the immunogen sequence, it is quite likely ab62321 will also cross react with the IGF1 receptor at P-Tyr 1161.

    Read More

    Answer

    Thank you for contacting us.

    Acoording to information UniProt/SwissProt information (http://www.uniprot.org/uniprot/P06213), the insulin receptor peptide is cleaved into the following 2 chains, Apha and Beta:



    The Insulin receptor subunit alpha is from aa28 – aa758. This731aa chain contains three phospho sites: Modified residue 400 Phosphoserine, Modified residue 401 Phosphotyrosine, Modified residue 407 Phosphoserine.



    The Insulin receptor subunit beta chain is comprise of aa763 – aa1382. This 620aa chain contains twelve phospho sites.



    Review of the products on our catalog show that each of the phosho specific antibodies which we have for IR are specific to phospho sites beyond the aa758 site. Each of these products will recognize the Beta form.


    I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

    Use our products? Submit an Abreview. Earn rewards!
    https://www.abcam.com/abreviews

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up